ZUP1 and acute myeloid leukemia: Although the complexity of the DUB domains and the conservation of catalytic pockets pose challenges to the clinical development of small-molecule DUB inhibitors, recent X-ray crystallographic studies have demonstrated the possibility of designing selective and potent inhibitors with antitumor activity, as exemplified by the USP7 inhibitors that have therapeutic effects in AML in vivo models.